A second trefoil protein, ITF/hP1.B, is transcribed in human breast cancer

Breast Cancer Research and Treatment

Volumn 38, Issue 2, 1996, Pages 145-151

  Theisinger, Birgit ^a   Seitz, Gerhard ^b   Dooley, Steven ^a   Welter, Cornelius ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b KLINIKUM BAMBERG   (Germany)

Author keywords

Breast cancer; Trefoil proteins

Indexed keywords

ESTROGEN; PROTEIN; TREFOIL PEPTIDE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; GASTROENTERITIS; GENE ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ISOLATION;

BREAST NEOPLASMS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH SUBSTANCES; HUMANS; MUCINS; MUSCLE PROTEINS; NEOPLASM PROTEINS; NEUROPEPTIDES; PEPTIDE BIOSYNTHESIS; PEPTIDES; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0029937910     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806668     Document Type: Article

References (32)

1. Hoffmann W, Hauser F: The P-domain or trefoil motif: a role in renewal and pathology of mucous epithelia? Trends Biochem Sci 18: 239-243, 1993
2. Rio MC, Bellocq JP, Daniel JY, Tomasetto C, Lathe R, Chenard MP, Batzenschlager A, Chambon P: Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 241: 705-708, 1988
3. Tomasetto C, Rio MC, Gautier C, Wolf C, Hareuveni M, Chambon P, Lathe R: hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J 9: 407-414, 1990
4. Hanby AM, Poulsom R, Singh S, Elia G, Jeffery RE, Wright NA: Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology 105: 1110-1116, 1993
5. Podolsky DK, Lynch-Devaney K, Stow JL, Oates P, Murgue B, DeBeaumont M, Sands BE, Mahida YR: Identification of human intestinal trefoil factor. J Biol Chem 268: 6694-6702, 1993
6. Hauser F, Poulsom R, Chinery R, Rogers LA, Hanby AM, Wright NA, Hoffman W: hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Acad Sci USA 90: 6961-6965, 1993
7. Rio MC, Chenard MP, Wolf C, Marcellin L, Tomasetto C, Lathe R, Bellocq JP, Chambon P: Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 100: 375-379, 1991
8. Wright NA, Poulsom R, Stamp G, Van-Noorden S, Sarraf C, Elia G, Ahnen D, Jeffery R, Longcroft J, Pike C, et al.: Trefoil peptide gene expression in gastroenintestinal epithelial cells in inflammatory bowel disease. Gastroenterology 104: 12-20, 1993
9. Pichon MF, Milgrom E: Clinical significance of the estrogen regulated pS2 protein in mammary tumors. Crit Rev Oncol Hematol 15: 13-21, 1993
10. Henry JA, Bennett MK, Piggott NH, Levett DL, May FE, Westley BR: Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 64: 677-682, 1991
11. Luqmani YA, Ryall G, Shousha S, Coombes RC: An immunohistochemical survey of pS2 expression in human epithelial cancers. Int J Cancer 50: 302-304, 1992
12. Welter C, Seitz G, Blin N: Expression of the breast cancer-associated protein pS2 in adenosquamous carcinomas of the gastrointestinal tract. Acta Oncol 32: 315-317, 1993
13. Theisinger B, Welter C, Seitz G, Rio MC, Lathe R, Chambon P, Blin N: Expression of the breast associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma. Eur J Cancer 27: 770-773, 1991
14. Luqmani Y, Bennett C, Paterson I, Corbishley CM, Rio MC, Chambon P, Ryall G: Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer 44: 806-812, 1989
15. Máller W, Borchard F: pS2 protein in gastric carcinoma and normal gastric mucosa: association with clinicopathological parameters and patient survival. J Pathol 171: 263-269, 1993
16. Welter C, Theisinger B, Seitz G, Tomasetto C, Rio MC, Chambon P, Blin N: Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest 66: 187-192, 1992
17. Seitz G, Theisinger B, Tomasetto G, Rio MC, Chambon P, Blin N, Welter G: Breast cancer-associated protein pS2 expression in tumors of the biliary tract. Am J Gastroenterol 86: 1491-1494, 1991
18. Welter C, Theisinger B, Rio MC, Seitz G, Schuder G, Blin N: Expression pattern of breast-cancer-associated protein pS2/ BCEI in colorectal tumors. Int J Cancer 56: 52-55, 1994
19. Wysocki SJ, Hahnel E, Masters A, Smith V, McCartney AJ, Hahnel R: Detection of pS2 messenger RNA in gynecological cancers. Cancer Res 50: 1800-1802, 1990
20. Horwitz KB, McGuire WL: Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 253: 2223-2228, 1978
21. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957
22. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987
23. Masiakowski P, Breathnach R, Bloch J, Cannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895-7903, 1982
24. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888, 1980
25. Henry JA, Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR, May FE: pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 63: 615-622, 1991
26. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51: 624-628, 1991
27. Predine J, Spyratos F, Prud'homme JF, Andrieu C, Hacene K, Brunet M, Pallud C, Milgrom E: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy. Cancer 69: 2116-2123, 1992
28. Cappelletti V, Coradini D, Scanziani E, Benini E, Silvestrini R, Di-Fronzo G: Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur J Cancer 28A: 1315-1318, 1992
29. Koerner FC, Goldberg DE, Edgerton SM, Schwartz LH: pS2 protein and steroid hormone receptors in invasive breast carcinomas. Int J Cancer 52: 183-188, 1992
30. Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23: 239-248, 1993
31. Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Bruscagnin G: PS2 in breast cancer - alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 68: 374-379, 1993
32. Foekens JA, Rio MC, Sequin P, van-Putten WL, Fauque J, Nap M, Klijn JG, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832-3837, 1990